{"id":59575,"date":"2026-03-16T14:10:51","date_gmt":"2026-03-16T06:10:51","guid":{"rendered":"https:\/\/flcube.com\/?p=59575"},"modified":"2026-03-16T14:10:52","modified_gmt":"2026-03-16T06:10:52","slug":"abbiskos-irpagratinib-doses-first-patient-in-phase-ii-hcc-trial-fgfr4-inhibitor-plus-toripalimab-bevacizumab-targets-first-line-liver-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59575","title":{"rendered":"Abbisko&#8217;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer"},"content":{"rendered":"\n<p><strong>Abbisko Therapeutics Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG: 2256<\/a>) announced <strong>first patient dosing<\/strong> in a <strong>Phase II clinical study<\/strong> evaluating <strong>irpagratinib<\/strong> in <strong>combination with standard therapy<\/strong> (toripalimab plus bevacizumab biosimilar) for <strong>first-line advanced or unresectable hepatocellular carcinoma (HCC)<\/strong>. The <strong>highly selective oral FGFR4 inhibitor<\/strong> targets the <strong>FGF19 signaling pathway<\/strong>, which is <strong>overexpressed in ~30% of HCC patients<\/strong> and drives <strong>PD-L1 upregulation, immune evasion, and metastasis<\/strong>. The <strong>triple combination<\/strong> aims to <strong>enhance anti-tumor activity<\/strong> through <strong>complementary mechanisms<\/strong>, addressing a <strong>significant subset of patients<\/strong> who may <strong>resist standard immunotherapy<\/strong> alone.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-overview\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Irpagratinib (oral FGFR4 inhibitor)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Toripalimab (PD-1 mAb) + bevacizumab biosimilar<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line advanced or unresectable hepatocellular carcinoma (HCC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>FGF19-overexpressing subset (~30% of HCC)<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First patient dosed<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>Abbisko Therapeutics (HKG: 2256)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Irpagratinib Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Highly selective, oral small molecule FGFR4 inhibitor<\/td><\/tr><tr><td><strong>Target Pathway<\/strong><\/td><td>FGFR4\/FGF19 signaling<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>\u2022 Blocks FGF19-mediated FGFR4 activation<br>\u2022 Inhibits PD-L1 upregulation<br>\u2022 Reduces immune evasion and tumor metastasis<\/td><\/tr><tr><td><strong>Scientific Rationale<\/strong><\/td><td>FGF19 pathway activation weakens immunotherapy efficacy; FGFR4 inhibition restores immune sensitivity<\/td><\/tr><tr><td><strong>Prevalence<\/strong><\/td><td>FGF19 overexpression in up to 30% of HCC patients<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral administration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Combination Synergy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toripalimab (PD-1):<\/strong> Immune checkpoint blockade<\/li>\n\n\n\n<li><strong>Bevacizumab (anti-VEGF):<\/strong> Anti-angiogenesis; normalizes tumor vasculature for improved immune cell infiltration<\/li>\n\n\n\n<li><strong>Irpagratinib (FGFR4):<\/strong> Reverses FGF19-driven immune suppression; enhances PD-1 inhibitor efficacy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>HCC Market Burden<\/strong><\/td><td>China: 400,000+ annual cases; 50% of global incidence; 5-year survival &lt;15% in advanced disease<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Atezolizumab + bevacizumab (IMbrave150) dominates first-line; ~30% objective response rate<\/td><\/tr><tr><td><strong>FGF19 Biomarker<\/strong><\/td><td>Identifies subset with immune evasion mechanism; potential for enriched efficacy signal<\/td><\/tr><tr><td><strong>Abbisko Pipeline<\/strong><\/td><td>Irpagratinib anchors HCC strategy; FGFR4 selectivity differentiates from pan-FGFR inhibitors (fisogatinib)<\/td><\/tr><tr><td><strong>Toripalimab Synergy<\/strong><\/td><td>Leverages Junshi&#8217;s established PD-1; combination with bevacizumab biosimilar reduces cost<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>HCC Status<\/th><th>Irpagratinib Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>H3 Biomedicine\/Eisai<\/strong><\/td><td>Fisogatinib<\/td><td>FGFR4 inhibitor<\/td><td>Phase II (discontinued 2020)<\/td><td>Irpagratinib improved selectivity; combination with PD-1\/VEGF vs. monotherapy<\/td><\/tr><tr><td><strong>Blueprint Medicines<\/strong><\/td><td>BLU-554<\/td><td>FGFR4 inhibitor<\/td><td>Phase I\/II (limited activity)<\/td><td>Triple combination approach; FGF19 biomarker enrichment<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td>Atezolizumab + bevacizumab<\/td><td>PD-L1 + VEGF<\/td><td>Approved (1L HCC)<\/td><td>Irpagratinib adds FGFR4 blockade for FGF19+ tumors<\/td><\/tr><tr><td><strong>Abbisko<\/strong><\/td><td><strong>Irpagratinib + toripalimab + bev<\/strong><\/td><td><strong>FGFR4 + PD-1 + VEGF<\/strong><\/td><td><strong>Phase II<\/strong><\/td><td><strong>First triple combination targeting FGF19-mediated immune evasion<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II<\/strong><\/td><td>2026-2028<\/td><td>Efficacy in FGF19+ HCC; biomarker validation; safety\/tolerability of triple combination<\/td><\/tr><tr><td><strong>Expansion Cohorts<\/strong><\/td><td>2027-2028<\/td><td>FGF19-high vs. FGF19-low stratification; combination optimization<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2028-2030<\/td><td>Registrational study vs. standard of care in FGF19+ population<\/td><\/tr><tr><td><strong>Companion Diagnostic<\/strong><\/td><td>2026-2027<\/td><td>FGF19 IHC or ctDNA assay development for patient selection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II outcomes, FGF19 biomarker validation, and competitive positioning for irpagratinib in hepatocellular carcinoma. Actual results may differ due to combination toxicity, FGF19 testing adoption, and competitive dynamics with other FGFR4 inhibitors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031600116_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031600116_c.\"><\/object><a id=\"wp-block-file--media-dfc88d87-6ab1-479d-8dcb-ad877eac10c6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031600116_c.pdf\">2026031600116_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031600116_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dfc88d87-6ab1-479d-8dcb-ad877eac10c6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[186,62,921],"class_list":["post-59575","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-clinical-trial-approval-initiation","tag-hkg-2256"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbisko&#039;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59575\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbisko&#039;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer\" \/>\n<meta property=\"og:description\" content=\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59575\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T06:10:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T06:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbisko&#8217;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\\\/Bevacizumab Targets First-Line Liver Cancer\",\"datePublished\":\"2026-03-16T06:10:51+00:00\",\"dateModified\":\"2026-03-16T06:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbisko Therapeutics\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2256\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59575#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59575\",\"name\":\"Abbisko's Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\\\/Bevacizumab Targets First-Line Liver Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T06:10:51+00:00\",\"dateModified\":\"2026-03-16T06:10:52+00:00\",\"description\":\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59575\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59575#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbisko&#8217;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\\\/Bevacizumab Targets First-Line Liver Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbisko's Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59575","og_locale":"en_US","og_type":"article","og_title":"Abbisko's Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer","og_description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.","og_url":"https:\/\/flcube.com\/?p=59575","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T06:10:51+00:00","article_modified_time":"2026-03-16T06:10:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59575#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59575"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbisko&#8217;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer","datePublished":"2026-03-16T06:10:51+00:00","dateModified":"2026-03-16T06:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59575"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbisko Therapeutics","Clinical trial approval \/ initiation","HKG: 2256"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59575#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59575","url":"https:\/\/flcube.com\/?p=59575","name":"Abbisko's Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T06:10:51+00:00","dateModified":"2026-03-16T06:10:52+00:00","description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical study evaluating irpagratinib in combination with standard therapy (toripalimab plus bevacizumab biosimilar) for first-line advanced or unresectable hepatocellular carcinoma (HCC). The highly selective oral FGFR4 inhibitor targets the FGF19 signaling pathway, which is overexpressed in ~30% of HCC patients and drives PD-L1 upregulation, immune evasion, and metastasis. The triple combination aims to enhance anti-tumor activity through complementary mechanisms, addressing a significant subset of patients who may resist standard immunotherapy alone.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59575#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59575"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59575#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbisko&#8217;s Irpagratinib Doses First Patient in Phase II HCC Trial \u2013 FGFR4 Inhibitor Plus Toripalimab\/Bevacizumab Targets First-Line Liver Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59575"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59575\/revisions"}],"predecessor-version":[{"id":59577,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59575\/revisions\/59577"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}